Influence of Vitamin D Supplementation on Mental Health in Diabetic Patients: A Systematic Review
Abstract
:1. Introduction
2. Materials and Methods
2.1. The Registration and Design
2.2. The Assessment of Eligibility and Inclusion
2.3. The Systematic Review Procedure
2.4. The Procedure of Data Extraction
- (1)
- Basic details of the studies included in the systematic review, which include the design of the study, country/location, nature of the study group, and time;
- (2)
- Basic characteristics of the study participants, which include the number of participants and of female participants, age, and inclusion/exclusion criteria;
- (3)
- Basic description regarding the exposure and outcomes assessed in the included studies, which include vitamin D assessment, vitamin D supplementation, mental health outcome, and psychological measures;
- (4)
- Findings of the included studies, including observations and conclusions.
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33 (Suppl. 1), S62–S69. [Google Scholar] [CrossRef] [Green Version]
- Lin, X.; Xu, Y.; Pan, X.; Xu, J.; Ding, Y.; Sun, X.; Song, X.; Ren, Y.; Shan, P.F. Global, regional, and national burden and trend of diabetes in 195 countries and territories: An analysis from 1990 to 2025. Sci. Rep. 2020, 10, 14790. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization (WHO). Global NCD Target Halt the Rise in Diabetes. Available online: https://www.who.int/beat-ncds/take-action/policy-brief-halt-diabetes.pdf (accessed on 14 September 2021).
- Chireh, B.; Li, M.; D’Arcy, C. Diabetes increases the risk of depression: A systematic review, meta-analysis and estimates of population attributable fractions based on prospective studies. Prev. Med. Rep. 2019, 14, 100822. [Google Scholar] [CrossRef] [PubMed]
- Rotella, F.; Mannucci, E. Diabetes mellitus as a risk factor for depression. A meta-analysis of longitudinal studies. Diabetes Res. Clin. Pract. 2013, 99, 98–104. [Google Scholar] [CrossRef] [PubMed]
- Smith, K.J.; Béland, M.; Clyde, M.; Gariépy, G.; Pagé, V.; Badawi, G.; Rabasa-Lhoret, R.; Schmitz, N. Association of diabetes with anxiety: A systematic review and meta-analysis. J. Psychosom. Res. 2013, 74, 89–99. [Google Scholar] [CrossRef] [PubMed]
- Amiri, S.; Behnezhad, S. Diabetes and anxiety symptoms: A systematic review and meta-analysis. Int. J. Psychiatry Med. 2019, 2, 91217419837407. [Google Scholar] [CrossRef] [PubMed]
- Palamenghi, L.; Carlucci, M.M.; Graffigna, G. Measuring the Quality of Life in Diabetic Patients: A Scoping Review. J. Diabetes Res. 2020, 2020, 5419298. [Google Scholar] [CrossRef] [PubMed]
- Jing, X.; Chen, J.; Dong, Y.; Han, D.; Zhao, H.; Wang, X.; Gao, F.; Li, C.; Cui, Z.; Liu, Y.; et al. Related factors of quality of life of type 2 diabetes patients: A systematic review and meta-analysis. Health Qual. Life Outcomes 2018, 16, 189. [Google Scholar] [CrossRef] [PubMed]
- Ley, S.H.; Hamdy, O.; Mohan, V.; Hu, F.B. Prevention and management of type 2 diabetes: Dietary components and nutritional strategies. Lancet 2014, 383, 1999–2007. [Google Scholar] [CrossRef] [Green Version]
- Gray, A.; Threlkeld, R.J. Nutritional Recommendations for Individuals with Diabetes. In Endotext [Internet]; Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., de Herder, W.W., Dhatariya, K., Dungan, K., Grossman, A., Hershman, J.M., Hofland, J., et al., Eds.; MDText.com, Inc.: South Dartmouth, MA, USA, 2000. Available online: https://www.ncbi.nlm.nih.gov/books/NBK279012/ (accessed on 14 September 2021).
- Ozfirat, Z.; Chowdhury, T.A. Vitamin D deficiency and type 2 diabetes. Postgrad. Med. J. 2010, 86, 18–25. [Google Scholar] [CrossRef] [PubMed]
- Luo, B.A.; Gao, F.; Qin, L.L. The Association between Vitamin D Deficiency and Diabetic Retinopathy in Type 2 Diabetes: A Meta-Analysis of Observational Studies. Nutrients 2017, 9, 307. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Alcubierre, N.; Castelblanco, E.; Martínez-Alonso, M.; Granado-Casas, M.; Esquerda, A.; Traveset, A.; Martinez-Gonzalez, D.; Franch-Nadal, J.; Mauricio, D. Vitamin D deficiency is associated with poorer satisfaction with diabetes-related treatment and quality of life in patients with type 2 diabetes: A cross-sectional study. Health Qual. Life Outcomes 2018, 16, 44. [Google Scholar] [CrossRef] [PubMed]
- Vellekkatt, F.; Menon, V. Efficacy of vitamin D supplementation in major depression: A meta-analysis of randomized controlled trials. J. Postgrad. Med. 2019, 65, 74–80. [Google Scholar] [CrossRef]
- Shaffer, J.A.; Edmondson, D.; Taggart Wasson, L.; Falzon, L.; Homma, K.; Ezeokoli, N.; Li, P.; Davidson, K.W. Vitamin D supplementation for depressive symptoms: A systematic review and meta-analysis of randomized controlled trials. Psychosom. Med. 2014, 76, 190–196. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Spedding, S. Vitamin D and depression: A systematic review and meta-analysis comparing studies with and without biological flaws. Nutrients 2014, 6, 1501–1518. [Google Scholar] [CrossRef] [PubMed]
- Cheng, Y.C.; Huang, Y.C.; Huang, W.L. The effect of vitamin D supplement on negative emotions: A systematic review and meta-analysis. Depress. Anxiety 2020, 37, 549–564. [Google Scholar] [CrossRef]
- Hoffmann, M.R.; Senior, P.A.; Mager, D.R. Vitamin D supplementation and health-related quality of life: A systematic review of the literature. J. Acad. Nutr. Diet. 2015, 115, 406–418. [Google Scholar] [CrossRef] [PubMed]
- PROSPERO. International Prospective Register of Systematic Reviews. Available online: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=155779 (accessed on 9 October 2021).
- Głąbska, D.; Kołota, A.; Lachowicz, K.; Skolmowska, D.; Stachoń, M.; Guzek, D. The Influence of Vitamin D Intake and Status on Mental Health in Children: A Systematic Review. Nutrients 2021, 13, 952. [Google Scholar] [CrossRef] [PubMed]
- Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009, 6, e1000097. [Google Scholar] [CrossRef] [Green Version]
- Assessing Risk of Bias in Non-Randomized Studies. Chapter 13.5.2.3. Available online: http://handbook-5-1.cochrane.org/ (accessed on 28 July 2021).
- Wells, G.A.; Shea, B.; O’Connell, D.; Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available online: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed on 9 October 2021).
- You, S.; Kong, T.H.; Han, W. The Effects of short-term and long-term hearing changes on music exposure: A systematic review and meta-analysis. Int. J. Environ. Res. Public Health 2020, 17, 2091. [Google Scholar] [CrossRef] [Green Version]
- Westra, S.; Krul-Poel, Y.H.; van Wijland, H.J.; Ter Wee, M.M.; Stam, F.; Lips, P.; Pouwer, F.; Simsek, S. Effect of vitamin D supplementation on health status in non-vitamin D deficient people with type 2 diabetes mellitus. Endocr. Connect. 2016, 5, 61–69. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mager, D.R.; Jackson, S.T.; Hoffmann, M.R.; Jindal, K.; Senior, P.A. Vitamin D3 supplementation, bone health and quality of life in adults with diabetes and chronic kidney disease: Results of an open label randomized clinical trial. Clin. Nutr. 2017, 36, 686–696. [Google Scholar] [CrossRef] [PubMed]
- Penckofer, S.; Byrn, M.; Adams, W.; Emanuele, M.A.; Mumby, P.; Kouba, J.; Wallis, D.E. Vitamin D Supplementation Improves Mood in Women with Type 2 Diabetes. J. Diabetes Res. 2017, 2017, 8232863. [Google Scholar] [CrossRef] [PubMed]
- Fazelian, S.; Amani, R.; Paknahad, Z.; Kheiri, S.; Khajehali, L. Effect of Vitamin D Supplement on Mood Status and Inflammation in Vitamin D Deficient Type 2 Diabetic Women with Anxiety: A Randomized Clinical Trial. Int. J. Prev. Med. 2019, 12, 17. [Google Scholar] [CrossRef]
- Omidian, M.; Mahmoudi, M.; Abshirini, M.; Eshraghian, M.R.; Javanbakht, M.H.; Zarei, M.; Hasani, H.; Djalali, M. Effects of vitamin D supplementation on depressive symptoms in type 2 diabetes mellitus patients: Randomized placebo-controlled double-blind clinical trial. Diabetes Metab. Syndr. 2019, 13, 2375–2380. [Google Scholar] [CrossRef] [PubMed]
- Davoudi, M.; Allame, Z.; Niya, R.T.; Taheri, A.A.; Ahmadi, S.M. The synergistic effect of vitamin D supplement and mindfulness training on pain severity, pain-related disability and neuropathy-specific quality of life dimensions in painful diabetic neuropathy: A randomized clinical trial with placebo-controlled. J. Diabetes Metab. Disord. 2021, 20, 49–58. [Google Scholar] [CrossRef] [PubMed]
- Chel, V.; Wijnhoven, H.A.; Smit, J.H.; Ooms, M.; Lips, P. Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents. Osteoporos. Int. 2008, 19, 663–671. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- De Niet, S.; Coffiner, M.; Da Silva, S.; Jandrain, B.; Souberbielle, J.C.; Cavalier, E. A Randomized Study to Compare a Monthly to a Daily Administration of Vitamin D3; Supplementation. Nutrients 2018, 10, 659. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dalle Carbonare, L.; Valenti, M.T.; Del Forno, F.; Caneva, E.; Pietrobelli, A. Vitamin D: Daily vs. Monthly Use in Children and Elderly-What Is Going On? Nutrients 2017, 9, 652. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Revicki, D.A.; Kleinman, L.; Cella, D. A history of health-related quality of life outcomes in psychiatry. Dialogues Clin. Neurosci. 2014, 16, 127–135. [Google Scholar] [CrossRef] [PubMed]
- Trikkalinou, A.; Papazafiropoulou, A.K.; Melidonis, A. Type 2 diabetes and quality of life. World J. Diabetes. 2017, 8, 120–129. [Google Scholar] [CrossRef] [PubMed]
- Wändell, P.E. Quality of life of patients with diabetes mellitus. An overview of research in primary health care in the Nordic countries. Scand. J. Prim. Health Care 2005, 23, 68–74. [Google Scholar] [CrossRef] [PubMed]
- Keng, S.L.; Smoski, M.J.; Robins, C.J. Effects of mindfulness on psychological health: A review of empirical studies. Clin. Psychol. Rev. 2011, 31, 1041–1056. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Loucks, E.B.; Gilman, S.E.; Britton, W.B.; Gutman, R.; Eaton, C.B.; Buka, S.L. Associations of Mindfulness with Glucose Regulation and Diabetes. Am. J. Health Behav. 2016, 40, 258–267. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Darwish, L.; Beroncal, E.; Sison, M.V.; Swardfager, W. Depression in people with type 2 diabetes: Current perspectives. Diabetes Metab. Syndr. Obes. 2018, 11, 333–343. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Khuwaja, A.K.; Lalani, S.; Dhanani, R.; Azam, I.S.; Rafique, G.; White, F. Anxiety and depression among outpatients with type 2 diabetes: A multi-centre study of prevalence and associated factors. Diabetol. Metab. Syndr. 2010, 2, 72. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tovote, K.A.; Fleer, J.; Snippe, E.; Bas, I.V.; Links, T.P.; Emmelkamp, P.M.; Sanderman, R.; Schroevers, M.J. Cognitive behavioral therapy and mindfulness-based cognitive therapy for depressive symptoms in patients with diabetes: Design of a randomized controlled trial. BMC Psychol. 2013, 1, 17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Muñoz, R.F.; Beardslee, W.R.; Leykin, Y. Major depression can be prevented. Am. Psychol. 2012, 67, 285–295. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bertone-Johnson, E.R. Vitamin D and the occurrence of depression: Causal association or circumstantial evidence? Nutr. Rev. 2009, 67, 481–492. [Google Scholar] [CrossRef] [PubMed]
Criteria | |
---|---|
Inclusion |
|
Exclusion |
|
Ref. | Authors, Year | Design of the Study | Country/Location | Studied Group | Time |
---|---|---|---|---|---|
[26] | Westra et al. 2016 | Randomized, double-blind, placebo-controlled trial—SUNNY trial (StUdy the effect of vitamiN D supplemeNtation on glYcaemic control in type 2 DM) | Netherlands/in and around the city of Alkmaar | Adults with type 2 diabetes mellitus derived from general practitioners | July 2012 to April 2013 |
[27] | Mager et al., 2017 | Open-label randomized clinical trial | Canada/Northern Alberta | Adults with diabetes mellitus and chronic kidney disease from two clinics (Diabetes Nephropathy Prevention Clinic and Renal Insufficiency Clinic in the Northern Alberta) | 2011 to 2014 |
[28] | Penckofer et al., 2017 | Open-label, proof-of-concept study—Sunshine Study | United States of America/Chicago * | Women with type 2 diabetes mellitus and significant depressive symptomology | From October 2009 to May 2012 * |
[29] | Fazelian et al., 2019 | Randomized double-blind placebo-controlled clinical trial | Iran/Shahr-e-Kord | Women with type 2 diabetes mellitus, vitamin D deficiency, and anxiety recruited from Shahr-e-Kord Diabetes Clinic | Not specified |
[30] | Omidian et al., 2019 | Randomized placebo-controlled double-blind clinical trial | Iran | Patients with type 2 diabetes mellitus and mild to moderate depressive symptoms | Inclusion from October 2017 to May 2018 and follow up for 12 weeks |
[31] | Davoudi et al., 2021 | Randomized placebo-controlled clinical trial | Iran/Kermanshah | Patients with painful diabetic neuropathy and vitamin D deficiency referred to Beheshti hospital, Kermanshah, Iran | September 2019 to January 2020 |
Ref. | Number of Participants (Female Participants) Age (Mean/Median; SD/Range) | Inclusion Criteria | Exclusion Criteria |
---|---|---|---|
[26] | 187 (62) According to group: 67.0 ± 8.0 years for vitamin D supplementation group 68.0 ± 9.0 years for placebo group | Inclusion: aged ≥18 years; type 2 diabetes mellitus; treated with lifestyle advice, metformin, and/or sulfonylurea derivatives; serum HbA1c stable and ≤8.0% for the last three months without recent changes in hypoglycemic agents | Exclusion: insulin therapy; impaired renal function (GFR < 30 mL/min/1.73 m2); any granuloma forming disorder; hypercalcemia (serum calcium > 2.65 nmol/L); serum 25-hydroxyvitamin D (25(OH) D) <15 nmol/L or >150 nmol/L; urolithiasis; psychiatric treatment for schizophrenia; organic mental disorder or bipolar disorder currently or in the past; insufficient knowledge of the Dutch language; substance abuse (other than nicotine); increase in HbA1c to >8.5% within the study; hypersensitivity to cholecalciferol or placebo within the study; onset of urolithiasis within the study; any change in antidiabetic medication within the study; serum 25(OH)D <15 or >250 nmol/L within the study; taking vitamin D supplements other than planned within the study |
[27] | 120 (44) 65.32 (58.8–68.8) * | Inclusion: aged 18–80 years; type 1 or type 2 diabetes mellitus; stages 1–4 of chronic kidney disease (GFR 15–89 mL/min/1.73 m2) | Exclusion: co-morbid conditions known to affect vitamin D metabolism including gastrointestinal, liver, rheumatoid, or bone disorders (e.g., hyperthyroidism, untreated celiac disease, cancer, Paget’s disease, sarcoidosis, malabsorption); severe, permanent vision impairment; pregnancy; body mass of >136 kg; drug therapy known to interfere with vitamin D (e.g., oral glucocorticoids, cholestyramine, colestipol, mineral oil, Orlistat, digoxin); applying other forms of active vitamin D metabolites (e.g., calcitriol, vitamin D2); dialysis therapy or being on a kidney transplant list; pre-existing hypercalcemia (>2.75 mmol/L), hyperphosphatemia (>2.0 mmol/L), severe secondary hyperparathyroidism (PTH > 66 pmol/L), and serum 25(OH)D > 200 nmol/L; serum 25(OH)D < 37.5 nmol/L at time of screening; undergoing strict heavy exercise for weight control; using sunscreen lotion on a daily basis |
[28] | 50 (50) 54.3 ± 10.6 | Inclusion: women; aged ≥18; medically stable type 2 diabetes mellitus with HbA1c ≤9%; elevated depressive symptoms measured using the CES-D Scale; average score of ≥16 on the CES-D Scale from two screenings (phone and baseline) within 4 weeks of each screening | Exclusion: taking vitamin D supplementation during 2 months prior to enrolment; vitamin D levels ≥80 nmol/L; malabsorption problems (e.g., Crohn’s disease, celiac sprue) and/or bariatric surgery; hypercalcemia; severe complications of diabetes (e.g., amputation, blindness); low thyroid function; pregnancy; active suicidal ideation; history of bipolar depression; psychotic disorders; current alcohol or substance disorders |
[29] | 51 (51) According to group: 48.5 ± 7.6 years for vitamin D supplementation group 46.3 ± 11.2 years for placebo group | Inclusion: women; aged 20–60 years; diagnosis of type 2 diabetes mellitus based on the World Health Organization guidelines; mild, moderate, or severe anxiety; vitamin D deficiency or insufficiency (serum 25(OH)D of 25–75 nmol/L) | Exclusion: neurological or psychiatric disorders; taking any medications for depression or vitamin D/multivitamin supplements during the last 4 months; alcohol consumption; pregnancy; lactation |
[30] | 66 (27) According to group: 49.7 ± 6.5 years for vitamin D supplementation group 51.3 ± 5.9 years for placebo group | Inclusion: aged 30–60 years; type 2 diabetes mellitus; BMI 20–30 kg/m2; willingness to maintain the current diet, physical activity, and lifestyle for 3 months | Exclusion: receiving herbal products or dietary supplements for 3 months before and throughout the intervention; major depressive disorder and taking antidepressants; chronic kidney diseases; hepatobiliary diseases; gastrointestinal diseases; taking drugs that interact with vitamin D such as anticonvulsant drugs; using insulin or thiazolidinediones or anti-obesity drugs; pregnancy; lactation; any changes in the type or dosage of medications during the study; lack of adherence to the trial based on refusing to consume at least 90% of recommended treatments |
[31] | 204 (92) According to group: 56.3 ± 9.9 years for placebo group 53.3 ± 8.9 years for placebo + mindfulness group 54.8 ± 9.4 years for mindfulness group 54.5 ± 9.0 years for vitamin D supplementation group 56.6 ± 9.8 years for vitamin D supplementation + mindfulness group | Inclusion: age 20–70 years; type 2 diabetes mellitus; neuropathy; vitamin D insufficiency or deficiency (serum 25(OH)D of 25–75 nmol/L) | Exclusion: major co-morbid disease (e.g., coronary heart disease, psychiatric or neurological diseases); taking vitamin D or any multivitamins during the last three months; using any substance and drinking alcohol; pregnancy; more than one absence in mindfulness sessions |
Ref. | Vitamin D Assessment | Vitamin D Supplementation | Mental Health Component | Psychological Measure |
---|---|---|---|---|
[26] | 25(OH) vitamin D level in blood Sun exposure | 1250 µg/month vs. placebo for 6 months | Health-related quality of life (HRQOL) | The Dutch version of the Short Form 36 (SF-36) |
[27] | 25(OH) and 1,25(OH)2 vitamin D level in blood, 3-day food record | 50 µg/day vs. 1000 µg/month for 6 months | Health-related quality of life (HRQOL) | Short Form 36 (SF-36) |
[28] | 25(OH) vitamin D level in blood | 1250 µg/week for 6 months |
|
|
[29] | 25(OH) vitamin D level in blood, 3-day food record, Sun exposure | 1250 µg/2 weeks vs. placebo for 16 weeks | Depression, anxiety, stress | Depression, Anxiety, and Stress Scales (DASS-21) questionnaire |
[30] | 25(OH) vitamin D level in blood | 100 µg/day vs. placebo for 3 months | Depression | Persian version of Beck Depression Inventory-II (BDI-II-PERSIAN) |
[31] | 25(OH) vitamin D level in blood, 3-day food record, Sun exposure | 100 µg/day vs. placebo for 12 weeks | Health-related quality of life (HRQOL) | The Neuropathy Specific Quality of Life questionnaire (NeuroQol) |
Ref. | Observations | Conclusions |
---|---|---|
[26] | A small significant difference (adjusted β: −8.90; 95% CI: −17.16 to −0.65) between both groups was seen concerning the SF-36 domain role limitations due to physical problems in disadvantage of the vitamin D group. | Six months of vitamin D supplementation did not improve HRQOL in non-vitamin D-deficient people with type 2 diabetes mellitus managed on oral antidiabetic therapy. |
[27] | No significant differences over six months between groups were observed in quality of life measures (p > 0.05). | Daily (50 µg/day) and monthly (1000 µg/month) vitamin D3 supplementation for six months in adults with diabetes mellitus and CKD was safe, and resulted in equivalent adherence and improvements in overall vitamin D status, but only modest changes in quality of life (no significant changes). |
[28] | There was a significant decrease in depression (CES-D and PHQ-9, p < 0.001) and anxiety (state and trait, p < 0.001). An improvement in mental health status (SF-12, p < 0.001) was also found. After controlling for covariates (race, season of enrollment, baseline vitamin D, baseline depression (PHQ-9), and body mass index), the decline in depression remained significant (CES-D, p < 0.001). | This proof-of-concept study found that weekly administration of 1250 µg of vitamin D in women with type 2 diabetes mellitus who had significant depressive symptoms and low 25(OH)D levels had an improvement in depression, anxiety, and mental health outcomes. |
[29] | Anxiety score changes were significantly lower in vitamin D group than the controls (p = 0.001). Within-group comparison indicated that depression in supplement group with lower vitamin D levels was significantly reduced. | Vitamin D supplementation can improve mood status in female diabetics with anxiety and vitamin D deficiency. |
[30] | BDI-II scores decreased from 15.2 ± 9.6 to 9.8 ± 7.2 (p < 0.001) in the vitamin D group and 15.5 ± 11.2 to 13.7 ± 11.5 (p = 0.03) in placebo group. This decrease in BDI-II scores were significant (27.6 vs. 10.8%) compared with placebo (p = 0.02). | Supplementation of vitamin D in type 2 diabetes mellitus patients may protect patients against the onset of major depressive disorder. |
[31] | At the end-of-treatment, results showed improvement in all groups except the “placebo only” group for outcome variables. There was no difference between vitamin D and mindfulness groups (within and not combined with placebo) in posttest. However, “vitamin D + mindfulness” has a greater improvement rather than vitamin D and mindfulness groups (p < 0.05). | Combining vitamin D and mindfulness training can reduce pain severity and pain-related disability, so with these changes, patients experience improvement in their quality of life. |
Ref. | Association between Vitamin D Supplementation and Mental Health in Diabetic Adults | Quality | ||
---|---|---|---|---|
Studied Outcome | Supporting/Not Supporting a | Randomization against Placebo | Newcastle–Ottawa Scale (NOS) Score b | |
[26] | Health-related quality of life (HRQOL) | Not supporting | + | 9 |
[27] | Health-related quality of life (HRQOL) | Not supporting | - | 9 |
[28] | Depression, anxiety, mental health status | Supporting | - | 7 |
[29] | Depression, anxiety, stress | Supporting | + | 8 |
[30] | Depression | Supporting | + | 6 |
[31] | Health-related quality of life (HRQOL) | Supporting (for vitamin D combined with mindfulness training) | + | 7 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Guzek, D.; Kołota, A.; Lachowicz, K.; Skolmowska, D.; Stachoń, M.; Głąbska, D. Influence of Vitamin D Supplementation on Mental Health in Diabetic Patients: A Systematic Review. Nutrients 2021, 13, 3678. https://doi.org/10.3390/nu13113678
Guzek D, Kołota A, Lachowicz K, Skolmowska D, Stachoń M, Głąbska D. Influence of Vitamin D Supplementation on Mental Health in Diabetic Patients: A Systematic Review. Nutrients. 2021; 13(11):3678. https://doi.org/10.3390/nu13113678
Chicago/Turabian StyleGuzek, Dominika, Aleksandra Kołota, Katarzyna Lachowicz, Dominika Skolmowska, Małgorzata Stachoń, and Dominika Głąbska. 2021. "Influence of Vitamin D Supplementation on Mental Health in Diabetic Patients: A Systematic Review" Nutrients 13, no. 11: 3678. https://doi.org/10.3390/nu13113678
APA StyleGuzek, D., Kołota, A., Lachowicz, K., Skolmowska, D., Stachoń, M., & Głąbska, D. (2021). Influence of Vitamin D Supplementation on Mental Health in Diabetic Patients: A Systematic Review. Nutrients, 13(11), 3678. https://doi.org/10.3390/nu13113678